Drug Profile
Research programme: heart failure therapeutics - ARMGO Pharma
Alternative Names: Second generation Rycals® - ARMGO PharmaLatest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator ARMGO Pharma
- Class Antiarrhythmics; Heart failure therapies; Small molecules
- Mechanism of Action Ryanodine receptor calcium release channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Arrhythmias; Heart failure; Polymorphic catecholergic ventricular tachycardia
- Research Sarcopenia
Most Recent Events
- 26 Sep 2023 Early research in Sarcopenia in USA (unspecified route) (ARMGO Pharma pipeline, September 2023)
- 30 Dec 2022 Research programme for heart failure therapies is still in preclinical development in Arrhythmias in USA (Armgo Pharma pipeline, December 2022)
- 30 Dec 2022 Research programme for heart failure therapies is still in preclinical development in Heart-failure in USA (Armgo Pharma pipeline, December 2022)